Pharma Market Access Insights - from Petauri Evidence

Send us Fan MailHow will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch planning, pricing corridors, and payer expectations worldwide? How should global market access teams prepare for a more transparent and tightly connected pricing environment?MFN reform is already influencing how companies plan, price, and launch medicines around the world. While CMS proposals sit at the center of the debate, the implications extend far beyond the US. The increased transparency required in models under consideration has the potential to accelerate global price convergence, affect international reference dynamics, and place new pressures on evidence generation, launch sequencing, and global pricing corridors.This episode was first broadcast as a live webinar on Wednesday 15th April 2026. It is designed to help global and US teams understand and anticipate the worldwide strategic implications of MFN policy. The session brought together four experts offering global and US perspectives on MFN:Steve O’Malley (President, Petauri Advisors): Moderator and contributor on US access and strategic implicationsCatherine Beecher (Director – Global Pricing and Market Access, Petauri Evidence): Bringing insight into global evidence requirements, lifecycle planning, and cross‑market pricing pressuresClare Foy (Director – Global Pricing and Market Access, Petauri Evidence): Bringing expertise in global pricing strategy and launch planning across international marketsMichael Garner (Vice President, Artia Solutions – Powered by Petauri): Bringing US Medicaid expertise with a focus on CMS MFN proposals and their operational and strategic implicationsLearn more at: https://petauri.com/insights/global-market-access-strategy-for-mfn/In this webinar, we explored:The most recent CMS MFN policy developments and how models such as GENEROUS, GLOBE, and GUARD may evolveThe possible effects of the recent announcement of new tariffs on pharmaceutical manufacturersHow greater price transparency could affect international pricing corridors and global revenue forecastsImpacts on launched products, peri-launch assets, and early pipeline programs from both a global and US policy standpointStrategic options for optimizing ex-US price potential, including evidence generation, innovative agreements, conditional reimbursement, and launch sequencingHow global market access teams can build pricing and access strategies that remain resilient as MFN models evolveWider policy developments to monitor outside the US, including proposed changes to the exclusivity period in the EU, and the growing influence of the Joint Clinical AssessmentLearn more about our pricing and market access strategy services.Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region?For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare systems vary significantly between markets, regulatory and payer expectations differ, and health technology assessment (HTA) processes continue to evolve. These differences create both opportunities and challenges for Pharma and Medtech companies preparing evidence, developing global plans, and equipping local affiliates with the right materials to secure access.In this episode, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed four regional experts: For Argentina: Eleonora Aiello (CEO at Ceibo Health Consulting) For Brazil: Alessandra Calabró (Independent expert in market access and government affairs) For Colombia: María Fernanda Escobar (Principal Advisor, InnovaSalud) For Mexico: Fernando del Río (Partner at InnovaSalud, GP at XB Ventures)Together, they unpack the access landscape in their countries, sharing experience‑based insight to help global teams refine evidence plans and align global materials to local payer expectations.Together, they explore:Variation in healthcare systems, regulatory structures, and payer landscapes across LATAMHTA landscape in key markets and the influence of bodies such as CONITEC in Brazil, IETS in Colombia, CENETEC in Mexico, and ANEFiTS in ArgentinaDifferences in evidence expectations, including clinical, economic, and real‑world data requirementsHow global dossiers, value messages, and evidence packages can better support affiliates engaging with local payersOpportunities and challenges for introducing Pharma and Medtech innovations into LATAM marketsFuture policy, regulatory, and reimbursement developments to monitor across the regionThis episode was first broadcast as a live webinar on Thursday 19th March 2026. For more information about this webinar see: https://petauri.com/insights/latam-market-access-unlocked/For support with market access strategy and global launch, please reach out to [email protected] to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding?In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and service redesign, Yousaf explored how ICS pharmacy teams are adapting, and what this means for industry partners.This episode was first broadcast as live webinar on: Friday 24th October 2025.Learn more about this episode at https://petauri.com/insights/evolving-nhs-ics-chief-pharmacists-perspective/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?This episode explores Switzerland’s potential as an early launch market.In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.We discussed:- What makes Switzerland attractive as a first-launch market - Key differences between Swiss and European Union (EU) market access pathways - How to prepare for inclusion on the SL and what “economically efficient pricing” really means - The role of cantonal (state) variation and decentralised healthcare in shaping access - How Swiss decisions may be influenced by the EU’s JCA - What global teams can learn from Swiss strategy to inform broader launch planningThis episode was first broadcast as a live webinar on Thursday 16th October 2025Learn more at  https://petauri.com/insights/market-access-switzerland/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailIn this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence)Together, they explore the implications of changing NHS structure and policy, and what this means for your market access, stakeholder engagement, and product innovation strategies.This episode was first broadcast as a live webinar on 19th September 2025. Some to the topics discussed may evolve over time. This session was shaped by your questions. Key themes included: - Evolving NHS structures, policies, and practices – and what this means for industry - Strategic commissioning: where will it happen, and who will lead it?- The 10 Year Plan and its implications for innovation and access - How industry can adapt to new engagement models and financial constraints - What the shift to integrated neighbourhoods means for product rollout and service designLearn more at: https://petauri.com/insights/evolving-nhs-landscape-policy-to-practice/For support with navigating the evolving NHS and launching new medicines and products in England, please email [email protected]. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailUncover the forces driving change in global pricing and accessIn this expert-led discussion we explore the latest trends, challenges, and strategic considerations shaping global pricing and market access (GPMA).At Petauri Evidence, our Global Pricing and Market Access Team are growing to meet the increasing complexity of global launch and access, bringing together fresh perspectives and decades of real-world experience. In this episode, our experts, Clare Foy and Adam Brown, are joined by two new additions to the team, Catherine Beecher and Sam Davies, who bring extensive expertise from both consultancy and industry.Ben Spurr (Head of Partnerships, Petauri Evidence) hosts the panel discussion with Clare, Adam, Catherine, and Sam as they explore the key issues facing Pharmaceutical and Medtech companies as they prepare for global launch, navigate payer expectations, and develop value-driven pricing strategies.This episode was first broadcast as a live webinar. Learn more at: https://petauri.com/insights/webinar-global-pricing-market-access-strategies/Discover our global pricing and market access services at: https://petauri.com/gpma/ To explore your pricing and market access strategy with our experts or to put your question to the panel, email [email protected] to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailDiscover a smarter way to manage and share market access resources with local affiliatesAre your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? In this webinar we discussed how a centralised platform can streamline resource sharing, ensure access to nationally-relevant evidence, and put the resources your local affiliates need right at their fingertips. The webinar features a conversation with Tim Styche (Market Access & Health Outcomes Director, Smith+Nephew), who shares how his team has solved this challenge with our Global Value Platform.Learn more at: https://petauri.com/insights/transforming-global-market-access-smarter-resource-management-with-local-affiliates-a-live-webinar/To discuss your needs or arrange a full demo of the platform email [email protected]  Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US?In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access leads in the US. Louise puts your questions to: - Rory Davies – Vice President of Value and Access, Petauri Advisors, with extensive past experience in Chief Clinical roles at Cigna, Flipt and WellDyne - Dan Vanderpoel – Executive Vice President, Strategic Payer Marketing; Head, Client Solutions, Petauri and former Manager, Trade Relations at Humana - Shana Gunderson Hua – Vice President of Value and Access, Petauri Advisors and former Medical Affairs Executive Director at Genentech and former AVP of Pharmaceutical Strategy and Contracting at Cigna and Express Scripts (now Evernorth)We explore what global market access teams need to know about market access and payer engagement in the US. We  explore how and why value messaging, pricing, and launch strategies are developed differently for the US market, compared to other key launch markets, and what this means for global teams preparing for US launch or taking a US-developed proposition internationally.Learn more at: https://petauri.com/insights/communicating-value-to-us-payers-insights-for-pharma-and-medtech/This episode was first broadcast live as a webinar in March 2025. Learn more about Petauri Evidence: https://petauri.com/petauri-evidence/Learn more about Petauri Advisors: https://petauri.com/petauri-advisors/Meet the ACE team: https://petauri.com/about-us/ace-team/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailDiscover how health economics can support successful Medical Device launch, proposition development, and market accessThis episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics).See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/This episode was originally broadcast live as webinar in February 2025. https://petauri.com/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.They explore:The evolving payer evidence landscape in the USPreferences for clinical and economic evidence by US payersKey differences between the US and other global markets with regard to evidence, HEOR, and market accessOpportunities and challenges when launching new medicines/medical devices/diagnostics in the USInnovative perspectives on evidence planning and strategy for the US marketUS payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer surveyThis episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our expertsThis episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/For support with real-world evidence analysis, health economic modelling of health technology assessment, email [email protected] or visit https://mtechaccess.co.uk/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Place and ICB levelSpecific challenges and pressures facing the NHS now and in the run up to winterImmediate and long-term impact of (expected) new government policiesHow industry can best support the NHS as it plans for winter and beyondHow your field teams can engage with NHS commissioners over the next few monthsThis episode was first broadcast as a live webinar in August 2024.Learn more at https://mtechaccess.co.uk/nhs-winter-planning/For support with your UK market access and NHS engagement strategy, visit: https://mtechaccess.co.uk/strategic-uk-market-access/ or email [email protected] to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailAre you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS from both sides of the fence: as a PCN Clinical Director and GP Partner, and as a HealthTech and Venture Capital Consultant.The NHS in England is complex and ever changing. Recent years have seen the introduction of new structures, new decision-makers and new priorities. If you’ve fallen out of the loop of what’s happening with the NHS, this webinar is here to help.After de-ciphering some of the new(er) NHS terminologies and structures, we discuss:The key steps for introducing a new health technology to the NHSWho to speak to, when and whereWhat to include in your value proposition to appeal to NHS decision-makers How to best meet key stakeholders’ needsThe challenges of bringing a new technology to the NHS in EnglandLearn more about this webinar at: https://mtechaccess.co.uk/de-mystifying-the-nhs/Discover more about how we can support your UK launch strategy at: https://mtechaccess.co.uk/strategic-uk-market-access/ This webinar was first broadcast live as a webinar in July 2024Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:- Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chief Officer for North West Surrey Health and Care Alliance) - Zafran Azam (Head of Medicines Optimisation and Delivery, Derby City Place)- Dr Neil Forster (GP and PCN Clinical Director, Northumberland Medical Alliance)We  explore:- Where NHS primary care is heading and what this means for your strategy and business planning- Prescribing and decision-making in primary care- The implications of the GP Contract for PCNs, GPs, patients, and industry- What this means for integration and the integrated care model- Policy priorities in practice and what to expect in an election year- How Pharma, Medtech, and Diagnostics companies can best engage with primary care leadersLearn more at: https://mtechaccess.co.uk/nhs-primary-care-gp-contract/Discover more about our UK market access services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailDiscover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how Connected Insights data visualisation dashboards can help your teams have strategic conversations with healthcare decision-makers. Iain also explains typical use cases for the dashboards for field teams, why data dashboards are useful for the NHS, and what sets Connected Insights dashboards apart.Learn more about this showcase at: https://mtechaccess.co.uk/engage-nhs-with-rwd/Learn more about real-world data visualisation at: https://mtechaccess.co.uk/digital-capabilities/real-world-data-market-access/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025?  In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:The market access landscape in CanadaUpcoming changes at CADTHWhat Canadian payers expect from your value propositionOpportunities and challenges when launching new medicines/medical devices/diagnostics in CanadaHow Canada compares to the USA/key European launch marketsWhat this means for your global market access strategyThis episode was first broadcast as a live webinar in March 2024. Learn more at https://mtechaccess.co.uk/market-access-canada-changes-cadth/Learn more about the Canadian healthcare market and launching new pharma and medtech innovations at: https://mtechaccess.co.uk/launching-healthcare-products-in-canada/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhere will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar,  our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to: - Overall and rare disease patient populations - Access inequalities - Time to diagnosis - Access to innovation timelines - Healthcare funding - Health technology assessment frameworksRobert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.Learn more at and request a copy of the webinar slides at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhich decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, nine counties and a resident population of over 5.5 million patients stretching from Gloucestershire and Wiltshire to the Isles of Scilly.The interview was led by David Thorne (Principal Consultant, Mtech Access and Transformation Director at Well Up North Primary Care Network [PCN]) who put both the NHS and industry perspectives to Richard to explore the real state of the NHS.In this episode, David and Richard discuss:- Where the NHS is heading and what this means for your strategy and business planning- Decision making, finances, and funding flows across the NHS- The role of NHS Regions, particularly with key funding decisions like Specialised Commissioning- Delivering service change across integrated systems- Policy priorities in practice and what to expect in an election year- How Pharma, Medtech, and Diagnostics companies can best engage NHS leaders at Region levelThis episode was first broadcast as a live webinar in February 2024. Learn more about the webinar and Richard at: https://mtechaccess.co.uk/how-does-funding-flow-in-nhse-regions/Discover more about our NHS Insights services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Partner, GP Federation Chief Officer, Viaduct Care). Together we explored what all this uncertainty means for NHS decision-making, day-to-day operations, strategy, and engagement with industry.In this webinar, we bring together leaders from across the NHS to explore how they are planning and operating in this uncertainty.We explore: - Strategy and planning in these times of uncertainty - What’s happening with GP contracts - Financial pressures and challenges - If/where it’s possible to drive forward change in the current environment - How Pharma and Medtech can best support NHS leaders - Where the panel would welcome solutions from industryPlease note this episode was first broadcast in January 2024 as a live webinar. Some aspects of policy discussed have evolved and continue to evolve. Discover more at:  https://mtechaccess.co.uk/nhs-policy-for-2024-25/Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat is health economic evaluation and which modelling approaches can be used to support market access activities?In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.Our specialists explore six of the most common health economic modelling structures used to support market access activities; - Decision trees - Markov models - Semi-Markov models - Partitioned survival models - Cox regression models - Discrete event simulationsThis episode was first broadcast as a live webinar in January 2024. For more information or to request a copy of the slides used, please visit: https://mtechaccess.co.uk/de-mystifying-health-economic-models/Work with our health economists:  https://mtechaccess.co.uk/health-economics/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHere, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?In this episode, our experts in HTA, health economics, and commercialisation explore:- How to identify and communicate the value of your product for patients and the wider healthcare system- How to build a robust evidence package for successful launch and commercialisation- Key requirements for the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) or Diagnostics Assessment Programme (DAP)- Next steps to take your innovation to healthcare leaders across the NHS and beyond, with an impactful customer communication strategyThis episode was first broadcast as a live webinar in January 2023. Learn more and request a copy of the slides at: https://mtechaccess.co.uk/evidence-strategy-for-medical-technologies-and-diagnostics/ Discover how Mtech Access can support your commercialisation journey at: https://mtechaccess.co.uk/medical-device-market-access/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.We take a step back from the intricacies of market access and HEOR, to explore the role our specialism plays in broader commercial and product strategy. We ask: where does market access and HEOR sit in this broader picture, and how can market access teams best support their product and company brand?Using the US market as our case study, we explore:- How to set up your product for success- Commercialisation routes in the US for Pharma and Medtech- The relationship between brand strategy and market access- What Pharma can learn from Medtech’s approach to commercialisation- What Medtech innovators can learn from Pharma companies’ approach to launchThis episode was first broadcast as a live webinar in January 2024. Learn more at: https://mtechaccess.co.uk/commercialisation-strategy-us-market/Explore our work in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/ Discover how Mtech Access can support you global market access and pricing strategy: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.Malcolm Qualie and David Thorne explored:Specialised commissioning in the NHSThe risks and opportunities that devolution to ICBs will bringWhat we can expect to see in the short and longer termHow industry can support ICB leaders through this transitionHow Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertaintiesLearn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/This episode first broadcast as a live webinar in Decmeber 2023. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience.In this NHS Whispers webinar, guest speaker Paul Mears shares his experiences leading a Welsh health board. The 7 Health Boards in Wales have been operating as integrated systems for over a decade. With the NHS in England just getting to grips with integration, we explore what England can learn from the Welsh experience.Robert and Paul explore: - How NHS Wales is structured and who the key decision makers are - How the integrated healthcare system works in Wales and how this differs to what’s happening in England - How priorities are set and what shapes decision-making at health board level - The nuances of the Welsh health system and what this means for industry - How Welsh Health Boards work with industry and the lessons here for ICBs and industry in England - Prudent healthcare and what this means in practice - How industry can best engage with health board leaders, what channels to use, and what messages to bringThis episode was first broadcast live as webinar in November 2023Learn more about this webinar at: https://mtechaccess.co.uk/integrated-care-in-nhs-wales/.Discover how we can help you with your NHS engagement and UK market access strategy at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailClare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).We explore:- The nature of the Italian market and the reimbursement process- Pricing and market access considerations when launching in Italy- What the reforms at AIFA mean for market access and managed entry agreements- How the AIFA changes specifically impact innovative products- Changes to early access programmes in Italy- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailDr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond.Former ‘GP of the year’ and strategic influencer over primary care policy, Dr Farzana Hussain, discusses the unmet needs in primary care, how primary care leaders are responding to these challenges, and where industry can best offer support.Phil and Farzana discuss: How unmet needs are identified in primary care, the processes followed, and datasets used to inform decision making The specific challenges facing primary care as we head into winter The role of PCN leaders and their impact on national policy How industry can best support and collaborate with PCNs Ongoing lessons from the pandemic and the vaccine roll-outLearn more about this webinar at: https://mtechaccess.co.uk/unmet-need-nhs-primary-care/ Discover or NHS Insight and UK market access services: https://mtechaccess.co.uk/uk-nhs-insights/This episode was first broadcast as a live webinar in October 2023. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow can our community support NHS leaders to deliver a data-led, people-centric health service?Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s population health management goals.Population health management has the potential to be a powerful tool for healthcare systems, effecting the way health and care is strategised, budgeted, targeted, and delivered. We see a future where key decisions in the NHS are driven by population health data. What we now need is a new way of working powered by local need, quality evidence and a systematic approach.In this webinar, Phil and Mark explore:  - How the NHS can use population health management to transform the system - The importance of community in population health management - How Pharma, Medtech, and the wider life sciences sector can work above brand to support the NHS with population health management - What a data-driven, people-centric approach means for the way treatments are valued - How population health management could transform the economics of healthcareThis episode was first broadcast as a live webinar on Friday 8th September 2023. Learn more at: https://mtechaccess.co.uk/uk-nhs-insights/ Discover more about our work in this area at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:- How, when and where AI is being used in clinical trials- How Lexitas are using AI in clinical trials for ophthalmology- Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development- What the future holds for AI in the development of new medicines- The role AI can play in selecting patients for clinical trials- The impact AI may have on the way we evaluate drug effectiveness- What this all means for evidence synthesis, health economics, reimbursement and market access- The future prospects of AI in pharmaceutical developmentLearn more at: https://mtechaccess.co.uk/ai-clinical-trials-evidence/This episode was first broadcast as a live webinar in August 2023. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for Medtech, Health technologies, and Medical Device market access.With the challenges of the pandemic and the changes brought in following Brexit, policy and compliance in the UK has been on shifting sands for several years now. With many predicting a change in government at the next election, this continues to be a time of uncertainty. What does this political landscape mean for health policy, the regulatory regime and market access?In this on-demand webinar, Rob asks Bill about 6 areas where Medtech should be paying attention:MHRA and new medical device regulatory regimeUK health and social care supply and procurementSustainability and social valueAddressing capacity challenges with effective health and social care packagesInnovationExport and import – the implications of BrexitThis episode was first broadcast as a live webinar in July 2023.  Learn more about this webinar at:  https://mtechaccess.co.uk/uk-health-policy-medtech-bhta-webinar/Learn more about our services for Medtech companies at: https://mtechaccess.co.uk/medical-device-market-access/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHere we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets.Clare and Stefan discuss: - Preparing for access to Switzerland – a European market outside the EU - Pricing strategy and HTA decision-making in Austria under the new Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) - Launching in Germany – is this still one of the most attractive European markets? - The Financial Stabilisation Act in Germany – what this means for drug pricingLearn more at: https://mtechaccess.co.uk/market-acce...This episode was first broadcast as a live webinar in July 2023. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow are nursing professionals supporting the digital evolution in UK healthcare? How can new technologies be leveraged by front-line clinical teams to support improved patient care? And how can Medtech, Digital and Biotech innovators collaborate with the front-line nursing teams in the NHS to drive transformation?Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) speaks to Jennie Smith, registered nurse, Medtech launch specialist and our new Director of NHS Insight & Interaction at Mtech Access.Phil and Jennie explore: - The transformative power of technology in the NHS; particularly on patient pathways - The role of nurses in digital transformation and the adoption and implementation of new technologies - Key nursing champions, including Chief Nurse Information Officers (CNIOs) - How industry can best support the NHS with digital transformation - Our plans to bring together NHS and industry for greater collaborationThis episode was originally broadcast as a live webinar in June 2023. Learn more at: https://mtechaccess.co.uk/nursing-driving-digital-change-nhs/Learn more about our NHS Insight & Interaction services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailIn this Global Whispers webinar we explore market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) speaks to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the challenges and opportunities for digital therapies to gain market access and ultimately improve patient outcomes.In the webinar, Clare asks Shefali about:The opportunities for digital technologies in neurology and how they may impact existing care pathways in the futureHow the digital technology market differs from the pharmaceutical marketRegulatory and reimbursement challenges for digital technologiesHer experiences in launching digital technologies in markets such as the US and GermanyHow digital technologies can be used to enhance and complement existing treatments/pathways of careLessons other digital health, medical device and pharmaceutical companies can learn from Shefali’s experiencesThe episode was first broadcast as a live webinar in June 2023.  Learn more about this webinar at https://mtechaccess.co.uk/market-access-for-digital-therapies/ Learn how Mtech Access can support you with your market access journey at: https://mtechaccess.co.uk/global-market-access-and-pricing/ Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat does it take to bring a cannabinoid pharmaceutical to market?We were delighted to welcome Michael Sassano (CEO – SOMAÍ Pharmaceuticals) as the first guest on our new Global Whispers webinar series. Michael shared with us his company’s experiences bringing new products to market, the challenges SOMAÍ Pharmaceuticals have faced and the lessons the Pharma industry can learn from their journey.In the webinar, Clare asked Michael about:- Drug development and clinical trial processes for medical cannabis products - Differences between the herbal medicines market and the Pharmaceutical market - Overcoming regulatory and reimbursement challenges - Finding the right place for cannabinoid medicines within existing pathways of care - Perceptions, pathways and routes to access in different markets - Lessons for the wider Pharma and Biotech industriesLearn more about this webinar and our guest speaker Michael Sassano at: https://mtechaccess.co.uk/global-market-access-journey-cannabinoid-pharmaceuticals/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow will changes to the structure of primary care impact decision making?How is the relationship between Integrated Care Boards (ICBs) and primary care stakeholders evolving? How will funding flows be impacted?Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Tim Goodson (Executive Officer, Dorset General Practice Alliance) to explore how primary care is evolving and what this means for decision making, funding, and relationships with industry.Phil and Tim explore:The integration journey across primary careEvolving relationships and structures in primary care in the NHSWhere decisions are made and who makes themHow understanding commissioning priorities and funding flows can help Pharma and Medtech to identify decision makers and understand their needsThis episode was first broadcast as a live webinar on Friday 28th April 2023. For more information please see: https://mtechaccess.co.uk/primary-care-integration-journey/.Learn more about how Mtech Access UK NHS Insight services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailIs data the key to transforming healthcare systems and patient care?What are the top priorities for digital transformation leaders in the NHS? How can Pharma and Medtech companies partner with the NHS to share data, transform services, and find smarter, faster way to improve patient care?Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Stephen Slough (Chief Digital Information Officer, NHS Dorset) to explore how, through the catalyst of partnership, new technologies and data have the potential to transform healthcare.We have reached a point where digital is so ubiquitous that, even in the NHS, what were previously seen as ‘digital’ transformation projects are now viewed as simply business transformation projects.Add in advancements in artificial intelligence and ChatGPT-type services, along with the potential of big data, and it’s no surprise that digital is at the heart of transformation in the NHS.In this episode, Phil and Stephen explore: - The digital landscape for NHS decision makers - How, when and where data can transform healthcare systems and patient care - How the NHS and industry can get access to and share our data to better plan products and services - What the top priorities are for digital leaders - How industry build strategic partnerships with Integrated Care Boards (ICBs) and other NHS leaders driving data-led transformationThis podcast was originally broadcast as a live webinar. Learn more at: https://mtechaccess.co.uk/data-led-transformation-nhs/ To learn more about our work with the NHS and how we support our Pharma and Medtech clients visit:  https://mtechaccess.co.uk/uk-nhs-insights/ Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow and where can innovation drive improvements in care and deliver better health for the population?How is the NHS looking to collaborate with key partners across industry and academia? What innovations are set to transform care? What role do Academic Health Science Networks (AHSNs) play and how can partners best engage with them?Prof Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Bill Gillespie (Chief Executive Officer, Wessex AHSN) to explore innovation in the NHS, the role of AHSNs and the potential for greater collaboration across our sector, in our latest NHS Whispers webinar.Learn more at: https://mtechaccess.co.uk/innovating-for-better-health/The episode was was originally broadcast as a live webinar on 24th February 2023. Discover our NHS Insights services and how we can support Medtech innovations achieve market access.Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWill NHS leaders, as part of an Integrated Care System (ICS), make conscious decisions to drive economic and social change?What social and economic value do ICSs offer the wider population they serve? How will industry support ICSs to deliver population-based health and social benefits?Prof Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Michael Wood (Head of Health Economic Partnerships, NHS Confed) for a far-reaching discussion around system integration, population health management, and the NHS’s social and economic potential.In December (2022), Michael Wood authored a report exploring one of the four key purposes of an ICS: to help the NHS support broader social and economic development. Michael’s NHS Confed report looked at the economics of healthcare and where broader strategic partnership working might lead system thinking in the NHS.Phil Richardson was one of several experienced ICS, local authority, university and professional experts that Michael invited to share their perspectives in the report.We were delighted to bring Michael and Phil together in this webinar to discuss these topics, particularly in light of what these new leadership purposes mean for the NHS’s relationship with the Pharmaceutical and wider Life Science industries.In the webinar, Phil and Michael discuss:NHS Confed and the links between the health sector and the economyThe need for ICS leaders to focus on broader social and economic developmentHow Pharma and Medical Device companies can add value to support this key ICS purposeWhy health and economic development is key to tackling health inequalitiesThe important role the NHS plays as an anchor institution that links better health with economic and social developmentWhat health and economic development could mean for funding at different levels of an integrated system – e.g. place based commissioningOpportunities for industry to step up and support the NHS with economic and social developmentLearn more about this webinar hereLearn more about our work with the NHSThis episode was first broadcast as a live webinar in January 2023Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailThe proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for specialised commissioning mean in practice.In this episode, we explore: - What’s new for Specialised Commissioning and what’s set to change? - What are the potential implications of the proposed changes recently published? - Integrated Care Boards (ICBs) and their increasing role with Specialised Commissioning - What this means for the NHS and for industry in practiceThe episode begins with an overview and analysis of the changes from David Thorne (Principal Associate, Mtech Access and Business Development Director, Well Up North PCN). David then opens up a broader discussion about the implications of these changes with our guest panellists James Curtis (Deputy Operational Director, Gloucestershire NHS Foundation Trust) and Mohammed Asghar (ICS Prescribing Governance Lead at Frimley Health and Care ICS).The episode was originally broadcast as a live webinar on 2nd December 2022. Learn more at: https://mtechaccess.co.uk/specialised-commissioning-nhs/Find our more about our NHS Insight and Interaction servicesSubscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWith so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can industry work with the NHS to improve patient flow to get people appropriate treatment sooner and limit the harm caused by waiting?  Prof Phil Richardson (new Chief Innovation Officer, Mtech Access and until recently, Executive Director at NHS Dorset ICS) joins Tom Clarke (Director, Mtech Access) explored all this and more.In this NHS Whispers webinar, we explore: - The pressures facing NHS systems and how this results in patients waiting - The long-term impact of this waiting; what it means for patients, their  - outcomes and treatment - What informs how NHS system leaders identify and approach these challenges - How health and care systems can make effective decisions in this climate - How Pharma and Medtech can support system leaders with these challengesThis webinar was first broadcast as a live webinar in November 2022. Learn more.Discover more about our NHS Insight and Interaction services.Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow is the NHS balancing competing challenges as we head through integration and towards winter? How are priorities set and what does system planning look like in primary care?Dr Alex Degan (Primary Care Medical Director, Devon Integrated Care System [ICS]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.In this episode, we explore how primary care leaders are reacting to the ongoing changes and challenges facing the NHS. Tom Clarke interviews primary care leader Alex Degan to explore:How priorities are set and what is driving changeWhat system planning looks like in primary careThe impact of integration – now in practice and for future planningHow Pharma and Medtech can best support primary careLearn more on our website.This podcast was first released as a live webinar on Friday 19th August 2022. Watch the webinar recording here. Learn more about how Mtech Access delivers authentic NHS insights to support your UK market access strategy. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailOn 1st July we saw the introduction of legislation for Integrated Care Systems (ICSs) in the NHS. In the weeks since, what has changed for healthcare leaders, practitioners and patients? What are the key priorities for NHS decision-makers and what is getting in the way of change? How can Pharma and Medtech support their NHS customers as they implement this change?In this episode  Tom Clarke (Director, Mtech Access) explored all this and more with Steve Reed (Head of Community Services, York Teaching Hospital NHS FT) and Dr Viren Mehta (Vice Chair, Viaduct Care and Clinical Director, Cheadle Primary Care Network).Together, they explore:What integrated care really means in practiceHow integrated the NHS really is at the momentWhat the key priorities are for those driving integration and leading ICSsWhat is getting in the way of change, and how industry can helpThis podcast was originally broadcast live as a webinar on Friday 22nd July 2022. Please see further details at https://mtechaccess.co.uk/ics-go-live-nhs-first-3-weeks/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat roles and responsibilities do Clinical Pharmacists have in the NHS? How can Pharma and Medtech engage Clinical Pharmacists, and how can industry best support these new decision-makers?Tom Clarke (Director, Mtech Access) explores all this and more with Tom Kallis (Senior Clinical Pharmacist, East Cornwall PCN).They explore the origins of the Clinical Pharmacist role and how it has become a key part of the primary care landscape, to understand how the responsibilities of those in the role have been growing. They discuss examples of specific, surprising, ways in which Clinical Pharmacists are expanding their skillsets and doing far more than just medicines use reviews and signing off prescriptions.Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailAs the NHS takes steps towards a more integrated future, how are systems and care pathways transforming? How is change being implemented, and what does this look like in reality for local systems and populations?Tom Clarke (Director, Mtech Access) explores all this and more with Debbie Morgan, (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust).Learn more about this webinar at https://mtechaccess.co.uk/transforming-systems-care-pathways-nhs/ and discover our NHS insight services at https://mtechaccess.co.uk/uk-nhs-insights/In this #WhispersWordsofWisdom webinar, Tom and Debbie explore the reality of transforming systems and care pathways in an NHS that’s moving towards an integrated future, asking:What does change look like for patients and their care pathways?How are systems changing, and how will decisions be made and implemented?What does this mean for Pharma and Medtech market access and industry’s engagement with the NHS?To understand how systems are approaching change, Debbie and Tom explore areas such as the elective recovery programme, virtual wards, and local population needs.As Director of Service Improvement and Transformation at Cambridge University Hospitals NHS Foundation Trust, Debbie leads the Trust’s improvement programme; engaging and empowering staff and patients on the journey of improvement and sustainability. She has previously held roles as Director of Commissioning and Head of Corporate Management at the Trust. Debbie originally joined the NHS in 1993 as a Clinical Cytogeneticist, before moving into NHS management in 2011. She has undertaken a wide variety of roles over the years, including commissioning and service improvement across the local health system, and has worked at director level for over 9 years.Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailOur experts in health economics, value communication, design and digital discuss how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams and KAMs, and healthcare customers. What does a best-in-class value communication tool look like in 2022? What are the key considerations when developing a new payer value toolkit? And what should Pharma and Medtech companies look for in a consultancy partner?For this webinar we brought together representatives from our health economics (Anthony Bentley), value communication (Lydia Crowe), design (Ryan Booth) and digital (Rob Pitt) teams to showcase how a typical Mtech Access project team collaborate to create interactive digital tools, with Emily Mair (Associate Consultant) acting as host presenter.Using our updated Digital Value Communication Tool Demo as a case study, our panellists explained how we craft our tools to meet the needs of three key groups:Those who commission the tools – e.g. market access, brand and commercial leadersThe end-users – e.g. key account managersThe audience – e.g. payers and other healthcare decision-makersLearn more at: https://mtechaccess.co.uk/digital-payer-value-communication-tools-webinar/This podcast was originally recorded as a live webinar. The webinar featured a run through of our new demo interactive budget impact model and and value proposition tool. This section has been cut from the podcast recording as it is highly visual.  Click here to see the demo video or visit our demo centre to explore the demo yourself. We'd love to show you more - email [email protected] to arrange a more detailed demo and discussion meeting. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat does population health management mean for the NHS, for patients, and for industry? How will the NHS translate population health management into impactful service change and what will this look like for patients?Tom Clarke (Director, Mtech Access) explores all this and more with guest speaker Dr Steven Laitner (GP, Parkbury House Surgery). Steven and Tom explore how the NHS can translate the theory of population health management into practical service changes that improve care for patients. They consider the role data will play, the challenges of limited data and whether a busy and tired health service can utilise population health data effectively. They also consider where and how Pharmaceutical and Medtech companies can support the NHS with population health management and service improvement.This episode was first released as a live webinar on 4th March 2022. Learn more about this webinar at: https://mtechaccess.co.uk/nhs-population-health-management/Learn more about the changing NHS environment for UK market access and our work at Mtech Access at: https://mtechaccess.co.uk/uk-nhs-insights/We are delighted that our podcast has been featured in this list of the Best 35 Pharma Podcasts by Feedspot: https://blog.feedspot.com/pharma_podcasts/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWhat does the ‘2022/23 priorities and operational planning guidance’ document mean for the NHS, for Integrated Care System (ICS) development and for an NHS workforce still battling COVID? How realistic and achievable are the priorities set out, and how can Pharma and Medtech best help NHS leaders to achieve these goals?Caroline Dawe (Deputy Director of Commissioning, Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more. The episode was first released live as a webinar on Friday 28th January 2022. Learn more about this webinar at: https://mtechaccess.co.uk/nhs-2022-23-priorities-operational-planning-guidance-webinar/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailPharma and Medtech professionals put questions to our panel of NHS associates as we reflected on the operational, structural, and clinical challenges the NHS has faced in 2021 and how Pharma and Medtech can best support the NHS in 2022.We were joined by some of Mtech Access’s closest and most insightful friends:- David Thorne (Director, Mtech Access and Well Up North PCN) our Policy expert- Patrick McGinley (Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust) our Hospitals and Finance expert- Liz Cross (Advanced Nurse Practitioner, Attenborough Surgery, Watford) our Primary Care and Clinical expert- Ewan Maule (Interim Chief Pharmacist, North East and North Cumbria ICS) our System and Medicines expertThis podcast was originally broadcast as a live webinar on 10th December 2021.Learn more at https://mtechaccess.co.uk/evolving-nhs-pharma-medtech-support-2022/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow will medicines be valued in the newly integrated world of the NHS? What are the risks and benefits of a single national formulary? What else is changing? And what does this mean for market access?Ellen Rule (Programme Director of the Gloucestershire Integrated Care System [ICS] and Director of Transformation and Service Redesign, Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more. Tom Clarke and Ellen Rule discuss the key points highlighted in her recent proposals ‘The systematisation of medicines optimisation: Why medicines optimisation is a priority for integrated care systems and how it can be improved’, including:The risks and benefits of a single national formulary and what this means for market accessHow to support system and local networks to implement pan-ICS approaches to medicines optimisationHow industry can distinguish their product in this new world where systems become automated to substitute generics and biosimilars for branded medicinesEllen and Tom discussed the implications of this paper, and the broader context of value in integrated care.For more information visit https://mtechaccess.co.uk/optimising-nhs-medicines-valued-integrated-systems/This podcast was originally recorded as a live webinar on 22nd October 2021. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailWe explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.Rob, Regina and Calum discuss:Current and future market events and trends for rare disease products across EuropeClinical evidence development, including tactical challenges around evidence generation and how to address theseBuilding the health economic case, including key principles and tactical nuances for health economic modelling in rare and orphan diseaseThis podcast was originally broadcast as a live webinar on 17th  November 2021.  To learn more and request a copy of the slides used please visit our website. Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence 

Send us Fan MailHow are healthcare systems looking differently at their population to deliver better care and what does this mean for future decision-making? How might the NHS re-imagine the hospital? What benefits can we expect from novel technologies, and can the NHS develop system resilience to improve healthcare outcomes?Dr Phil Webb (Chief Executive of Respiratory Innovation Wales) joined Tom Clarke (Director, Mtech Access) to explore all this and more. Re-imagining the hospital, investing in novel technologies, and developing system resilience to improve healthcare outcomes were all discussed. This episode also explores specific examples of how the Welsh Healthcare System is pushing itself to better care for the people it serves and where the obstacles to delivering change lie.As Chief Executive of Respiratory Innovation Wales, Phil has a remit for re-imagining care for people across Wales. He previously held roles within the Welsh Healthcare System responsible for Innovation and Service Development, and has commissioned services at national and local levels. Also having worked in Industry, Phil’s academic background includes health economics, epidemiology, statistics, and a doctorate in molecular biology.As such, we were interested to hear Phil’s perspective on everything from driving innovation in the NHS to the obstacles facing NHS systems, and how Pharma and Medtech can best help. This webinar is a must-see for anyone with an interest in how care systems are evolving further and faster than we could imagine, not just in Wales and respiratory care, but across all clinical and geographic areas.This episode was originally broadcast as a live webinar on Friday 17th September 2021.Learn more about our NHS insights services at https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more  news, insights and events from Petauri Evidence